Frequently asked questions
In 2022, the market for hepatitis D was estimated to be worth USD xx million.
The market for hepatitis D is anticipated to increase at a CAGR of 3.80% from 2023 to 2030, reaching USD xx million in 2030.
Serology tests are the most popular category of diagnostic tests.
Antiviral therapy, by the treatment modalities, is the notable segment.
During the projection period, the pegylated interferon alpha category is anticipated to exhibit the highest CAGR.
The hepatitis D market was ruled by North America.
The top players include BIOSIDUS, F. Hoffmann-La Roche Ltd, anoGen Healthcare Pvt. Ltd., AMEGA Biotech, Rhein-Minapharm, PROBIOMED SA de CV, 3SBio Group, Eiger BioPharmaceuticals, Hepion Pharmaceuticals, Inc., Antios Therapeutics, Inc., PharmaEssentia Corporation, Replicor, Janssen Pharmaceuticals, Inc., Apotex Corp., Mylan N.V, Aurobindo Pharma Limited, Gilead Sciences, Inc., GlaxoSmithKline, Zydus Pharmaceuticals, and others.
Government initiatives to increase awareness of hepatitis and its treatments, advancements in research and development, and increases in the prevalence of hepatitis D. These are the key drivers influencing the expansion of the global market.
Hepatitis D market growth is being constrained by issues with insufficient hepatitis D immunization, a lack of efficient therapies, expensive pricing, and mutual infection with hepatitis B.
Hepatitis D has a large global market opportunity due to the growth of clinical investigations and research, the discovery of specific antiviral drugs, improved diagnostic equipment, and the expansion of the healthcare network.